Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;13(2):173-181.
doi: 10.1111/1759-7714.14236. Epub 2021 Nov 17.

Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study

Masaki Ishida  1 , Kenji Morimoto  1 , Tadaaki Yamada  1 , Shinsuke Shiotsu  2 , Yusuke Chihara  3 , Takahiro Yamada  4 , Osamu Hiranuma  5 , Yoshie Morimoto  1 , Masahiro Iwasaku  1 , Shinsaku Tokuda  1 , Takayuki Takeda  6 , Koichi Takayama  1
Affiliations

Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study

Masaki Ishida et al. Thorac Cancer. 2022 Jan.

Abstract

Background: Chemoimmunotherapy has become a standard treatment option for patients with untreated advanced non-small-cell lung cancer (NSCLC). However, numerous patients with advanced NSCLC develop disease progression. Therefore, the selection of second-line treatment after chemoimmunotherapy is crucial for improving clinical outcomes.

Methods: Of 88 enrolled patients with advanced NSCLC who received chemoimmunotherapy, we retrospectively evaluated 33 who received second-line chemotherapy after progression of chemoimmunotherapy at six centers in Japan. Among them, 18 patients received docetaxel plus ramucirumab and 15 patients received single-agent chemotherapy.

Results: The objective response rate in patients treated with docetaxel plus ramucirumab was significantly higher than that in patients treated with a single-agent chemotherapy regimen (55.6% vs. 0%, p < 0.001). The median progression-free survival (PFS) of patients who received docetaxel plus ramucirumab and single-agent chemotherapy was 5.8 months and 5.0 months, respectively (log-rank test p = 0.17). In the docetaxel plus ramucirumab regimen group, patients who responded to chemoimmunotherapy for ≥8.8 months had a significantly longer response to docetaxel plus ramucirumab than those who responded for <8.8 months (not reached vs. 4.1 months, log-rank test p = 0.003). In contrast, in the single-agent chemotherapy group, there was no significant difference in PFS between the ≥8.8- and <8.8-month PFS groups with chemoimmunotherapy (5.0 vs. 1.6 months, log-rank test p = 0.66).

Conclusion: Our retrospective observations suggest that the group with longer PFS with chemoimmunotherapy might be expected to benefit from docetaxel plus ramucirumab treatment in second-line settings for patients with advanced NSCLC.

Keywords: chemoimmunotherapy; docetaxel plus ramucirumab; non-small-cell lung cancer; performance status.

PubMed Disclaimer

Conflict of interest statement

T.Y. received grants from Pfizer, Ono Pharmaceutical, Chugai Pharmaceutical, and Takeda Pharmaceutical. K.T. received grants from Chugai Pharmaceutical, Ono Pharmaceutical, and personal fees from AstraZeneca, Chugai Pharmaceutical, MSD, Eli Lilly, Boehringer Ingelheim, and Daiichi Sankyo. The other authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Consort diagram of the study
FIGURE 2
FIGURE 2
Kaplan–Meier curve for progression‐free survival (PFS) in non‐small‐cell lung cancer (NSCLC) patients who received (a) second‐line treatment, (b) second‐line treatment compared with docetaxel plus ramucirumab and single‐agent chemotherapy, (c) docetaxel plus ramucirumab compared with PFS 1st (≥8.8 vs. <8.8 months), and (d) single‐agent chemotherapy compared with PFS 1st (≥8.8 vs. <8.8). PFS 1st, PFS in chemoimmunotherapy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Miller KD, Goding Sauer A, Ortiz AP, Fedewa SA, Pinheiro PS, Tortolero‐Luna G, et al. Cancer statistics for Hispanics/Latinos, 2018. CA Cancer J Clin. 2018;68(6):425–45. - PubMed
    1. Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect of advances in lung‐cancer treatment on population mortality. N Engl J Med. 2020;383(7):640–9. - PMC - PubMed
    1. Gandhi L, Rodríguez‐Abreu D, Gadgeel S, Esteban E, Felip E, de Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non‐small‐cell lung cancer. N Engl J Med. 2018;378(22):2078–92. - PubMed
    1. Paz‐Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non‐small‐cell lung cancer. N Engl J Med. 2018;379(21):2040–51. - PubMed
    1. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first‐line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–301. - PubMed